
Ipsen, the manufacturer of Tazverik (tazemetostat), announced that effective immediately it is voluntarily withdrawing tazemetostat for the follicular lymphoma and epithelioid sarcoma indications in the US.
💊ow.ly/ASTx50YwsAi
💊ow.ly/2aZJ50YwsAj
#DrugNews

English

























